VIDEO: Recognizing importance of CNS penetration in EGFR-mutated lung cancer

ByRavi Salgia, MD, PhD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

In this video, Ravi Salgia, MD, PhD, highlighted two studies that investigated treatment for EGFR-mutated non-small cell lung cancer presented at ASCO Annual Meeting.

“What’s important for us to realize is [central nervous system] penetration,” Salgia, medical oncologist, professor and Arthur & Rosalie Kaplan Chair of the medical oncology and therapeutics research department at City of Hope, said. “Even for EGFR-mutated patients, CNS penetration is important.”

References:

Janne P, et al. Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Shu CA, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Salgia reports no relevant financial disclosures.

Take Homes in Lung Cancer

Read more

VIDEO: Recognizing importance of CNS penetration in EGFR-mutated lung cancer

References:

Related Content